1. Home
  2. ACIU

as of 12-17-2025 11:39am EST

$3.08
$0.21
-6.38%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Chart Type:
Time Range:
Founded: 2003 Country:
Switzerland
Switzerland
Employees: N/A City: N/A
Market Cap: 213.3M IPO Year: 2016
Target Price: $10.00 AVG Volume (30 days): 1.4M
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.90 EPS Growth: N/A
52 Week Low/High: $1.43 - $4.00 Next Earning Date: 11-04-2025
Revenue: $5,482,957 Revenue Growth: -89.33%
Revenue Growth (this year): -83.87% Revenue Growth (next year): 738.95%

Latest AC Immune SA News

ACIU Breaking Stock News: Dive into ACIU Ticker-Specific Updates for Smart Investing

All ACIU News

Share on Social Networks: